期刊文献+

基因组检测综合分析在骨髓增生异常综合征诊治中的应用 被引量:3

Comprehensive Analysis of Genomic Detection for a Patient with Myelodysplastic Syndrome
下载PDF
导出
摘要 本研究通过1例骨髓增生异常综合征(MDS)患者综合的分析,探讨基因组检测综合信息在MDS诊断、治疗方案选择以及预后评估的意义;采用核型分析、荧光原位杂交(FISH)及基于单核苷酸多态性的高分辨基因芯片分析(SNP-Array)检测患者染色体变化,采用新一代测序技术(NGS)检测患者的50肿瘤相关基因热点突变,对MDS的患者基因组信息进行综合分析。结果表明,G-带骨髓染色体核型分析检测到5号染色体长臂部分缺失和11号染色体长臂部分缺失,并得到FISH检测结果确认。SNP基因组芯片分析检测到两处获得性基因组大片段缺失,81 Mb的5号染色体长臂中间缺失以及24 Mb的11号染色体长臂中间缺失及2处获得性杂合缺失,分别是58 Mb的1号染色体的短臂末端和39 Mb 14号染色体长臂末端。此外,SNP基因组芯片分析检测到多条染色体的多个区域存在胚系发生的连续的大片段杂合性缺失,约占常染色体基因组的5.86%,提示患者父母具有3级亲属的血缘关系。50肿瘤基因热点突变检测未检出明显临床意义的基因突变信息,但在其中的6个基因中发现了6个基因位点的多态性,包括APC,FGFR3,KDR,KIT,PDGFRA和RET。结论:多种基因组学检测技术并用为患者提供了基因组学异常的全貌,其中一些发现对于患者的诊断、治疗方案的选择和预后很有意义,同时胚系基因组中存在的大片段杂合性缺失为遗传咨询提供有用的信息,也为MDS发病机制的研究提供线索。 This study was purposed to investigate the significance of genomic comprehensine analysis information in diagnosis, therapy and prognosis of MDS through comprehensive analysis of a patient with MDS. The bone marrow specimen from a patient with MDS was comprehensively analyzed by a combination of genomic approaches, including chromosomal karyotyping, fluorescence in situ hybridization (FISH), genome scanning using Affymetrix high density SNP microarray platform, and next-generation sequencing (NGS) analysis using IonTorrent Cancer Gene Panel. The results showed that an abnormal clone was identified by standard G-banding karyotyping and confirmed by FISH, which contains interstitial deletions on the long arms of chromosome 5 and 11 respectively. SNP-array analysis defined the two genomic deletions to be an 81 Mb interstitial deletion on the long are of chromosome 5 and a 24 Mb interstitial deletion on the long are of chromosome 11. Meanwhile, SNP-array detected two genomic regions with acquired loss of heterozygosity (LOH), a 58 Mb region on the short arm of chromosome 1 and a 39 Mb region on the distal end of the long arm of chromosome 14. In addition, SNP-array identified multiple genomic regions with long stretch of absence of heterozygosity, representing about 5.3 % of autosomal genome, indication a certain level of consanguinity between the parents. No clinically significant gene mutation was identified using IonTorrent 50 Cancer Gene Panel while 6 polymorphisms within 6 genes were observed including APC, FGFR3, KDR, KIT, PDGFRA, and RET. It is concluded that the combined genomic techniques are necessary to provide a full picture of the patient's genomic alterations. Some of the acquired genomic findings are important for the diagnosis and therapy selection. Germline genomic alterations warrant genetic counseling and are useful for further studies to explore the mechanisms leading to tumorigenesis of MDS patient.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2013年第6期1501-1506,共6页 Journal of Experimental Hematology
关键词 骨髓增生异常综合征 染色体核型分析 荧光原位杂交 基因组芯片分析 下代基因测序技术 myelodysplastic syndrome G-banding karyotyping fluorescence in situ hybridization SNP-based microarray next generation sequencing
  • 相关文献

参考文献17

  • 1SH S, Campo E, NL H, WHO Classification of Tumors ofHaematopoietic and Lymphoid Tissues. Lyon, France : IARCPress, 2008; (4th) : 88 -93.
  • 2Greenberg PL, Tuechler H, Schanz J, et al. Revised internationalprognostic scoring system for myelodysplastic syndromes. Blood,2012;120(12) :2454-2465.
  • 3Malcovati L, Germing U, Kuendgen A, et al. Time-dependentprognostic scoring system for predicting survival and leukemicevolution in myelodysplastic syndromes. J Clin Oncol,2007 ; 25(23) :3503 -3510.
  • 4Thiel A,Beier M,Ingenhag D,et al. Comprehensive array CGHof normal karyotype myelodysplastic syndromes reveals hiddenrecurrent and individual genomic copy number alterations withprognostic relevance. Leukemia, 2011 ;25(3) :387 -399.
  • 5Tiu RV, Gondek LP, O'Keefe CL,et al. Prognostic impact of SNParray karyotyping in myelodysplastic syndromes and related myeloidmalignancies. Blood, 2011 ;117( 17) :4552-4560.
  • 6Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect ofpoint mutations in myelodysplastic syndromes. N Engl J Med,2011 ;364(26) :2496 -2506.
  • 7List A, Dewald G, Bennett J, et al. Lenaiidomide in themyelodysplastic syndrome with chromosome 5q deletion. N Engl JMed, 2006;355(14) : 1456 - 1465.
  • 8Giagounidis AA, Germing U, Strupp C, et al. Prognosis of patientswith del(5q) MDS and complex karyotype and the possible role oflenaiidomide in this patient subgroup. Ann Hematol, 2005 ;84(9):569 -571.
  • 9Borze I,Juvonen E, Ninomiya S, et al. High-resolution oligo-nucleotide array comparative genomic hybridization study andmethylation status of the RPS14 gene in de novo myelodysplasticsyndromes. Cancer Genet Cytogenet, 2010;197(2) :166 - 173.
  • 10Lubbert M, Wijermans P, Kunzmann R, et al. Cytogeneticresponses in high-risk myelodysplastic syndrome following low-closetreatment with the DNA methylation inhibitor 5 -aza-2'-deoxycy-tidine. Br J Haematol, 2001 ;114(2) :349 -357.

同被引文献21

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部